What question did this study set out to answer?

This paper aims to unify concepts across pharmacology, drug discovery, and AI-driven design through the ITU framework.

May 19, 2026Open Access

ITU and Pharmacology: A Single-Axiom View of Drug Discovery, Receptor Pharmacology, ADME, Pharmacogenomics, Antibody Medicines, Vaccines and Immunotherapy, AI Drug Design, and FDA Regulation — Pass-1 Extension Paper #2, Block B 6/6 COMPLETE

Key Points

This paper aims to unify concepts across pharmacology, drug discovery, and AI-driven design through the ITU framework.
Phase analysis of drug discovery and pharmacology across eight categories including receptors, AI, and FDA regulation.
Integration of data from historical drug success rates, Nobel Prize achievements, and current trends in pharmacological interventions.
Development of strong couplings between multiple pharmacological contexts and prediction of future advancements.
Identify that 33% of FDA drugs target GPCRs, with an overall success rate of 1.5% in drug pipelines.
Report on significant advancements in antibody therapies and vaccines, including 95% efficacy of BNT162b2 and groundbreaking CAR-T therapies.
Predict 5+ FDA approvals for AI-designed drugs by 2030 with high confidence (P=0.80).

Abstract

This is Tier 1 paper #32 of the Information-Theoretic Unification (ITU) programme (Terada 2026; concept DOI 10. 5281/zenodo. 20109209; Tier 0 v3. 0 at 10. 5281/zenodo. 20200156). It is the SECOND paper of Pass-1 extension and completes Block B (life sciences) to 6/6: #26 Immunology + #27 Microbiology + #28 Neuroscience + #29 Developmental Biology + #30 Genomics + #32 Pharmacology. Follows #31 Optics & Photonics (DOI 10. 5281/zenodo. 20257844). Introduces Kₚharma across 8 sub-states: Kₚharmaₜarget, KₚharmaPK, Kₚharmabiologic, Kₚharmaᵢmmune, KₚharmaAI, Kₚharmaᵣegulatory, Kₚharmaₚharmacogenomic, Kₚharmaₛmallₘol. Phase 228 establishes drug discovery and pharmacology foundation: DiMasi 2016 14-year / 2. 6 billion pipeline with 1. 5% overall success rate, GPCRs 800 human receptors with 33% of all FDA drugs targeting them, Imatinib (Gleevec) 2001 BCR-ABL targeted therapy revolutionizing CML 5-year survival from 5% to 90% (Druker, OHSU), top selling drugs 2024 led by Keytruda 25B (Merck), Eliquis 13B, Ozempic 14B (Novo Nordisk). Phase 229 details receptor pharmacology: Lefkowitz-Kobilka Nobel Chemistry 2012 for β2-AR-Gs complex structure, MacKinnon Nobel Chemistry 2003 for KcsA K+ channel with K+/Na+ selectivity 10⁴×, GLP-1 evolution Exenatide 4% → Semaglutide 15% → Tirzepatide 22% → Retatrutide 24% weight loss, TRV130 oliceridine biased agonist FDA 2020, ITU axiom verified for Apo → Full and Apo → Biased agonist. Phase 230 covers ADME and pharmacogenomics: CYP3A4 metabolizes 50% of drugs, grapefruit-simvastatin 3× AUC increase (CYP3A4 inhibition), itraconazole 19× AUC, CYP2D6 PM 7% Caucasian, CYP2C19 PM 15-20% Asian, HLA-B*5701 abacavir 6% Caucasian (FDA preemptive testing 2007), TPMT/DPYD/UGT1A1 PGx, CPIC 100+ gene-drug pairs, PGx potentially reducing US 100, 000 annual ADR deaths by 30%. Phase 231 documents antibody medicines: Köhler-Milstein hybridoma Nobel 1984, antibody humanization murine→chimeric→humanized→fully human→AI-designed (immunogenicity 100%→1%), Trastuzumab (Herceptin) 1998, Pembrolizumab (Keytruda) 2014, ADC drugs (Kadcyla T-DM1 2013, Enhertu T-DXd 2019), Enhertu DESTINY-Breast04 NEJM 2022 HR for death 0. 64 in HER2-low breast cancer, bispecific antibodies (Blincyto BiTE 2014 first CD3×CD19 ALL, Hemlibra 2017 mimics FVIII with 87% bleeding reduction HAVEN-3 NEJM 2018, Tecvayli/Talquetamab/Epkinly 2022-23), ADC market 13B (2024) projected 50B (2030). Phase 232 reviews vaccines and immunotherapy: 6-generation vaccine evolution culminating in 2-week mRNA development time, Karikó-Weissman pseudouridine Nobel Physiology 2023 (38-year journey from 1985), BNT162b2 efficacy 95% (Polack 2020 NEJM), COVID vaccines 13 billion doses estimated saving 14. 4-19. 8 million lives (Watson 2022 Lancet Infectious Diseases), Allison-Honjo checkpoint Nobel Physiology 2018 reversing melanoma 5-year survival 5% to 60% over 2011-2022, CAR-T Kymriah pALL CR 83% (Maude 2018 NEJM), Yescarta/Brexucabtagene CD19, Abecma/Carvykti BCMA myeloma (Carvykti CR 67% CARTITUDE-1), Lifileucel first TIL therapy FDA February 2024. Phase 233 details AI drug discovery: Insilico Medicine INS018₀55 AI-designed in 21 days (Phase II IPF, TNIK inhibitor), Recursion Pharmaceuticals high-throughput cell imaging with Bayer partnership delivering 11 cardiovascular targets in 12 months, Atomwise AtomNet 700+ academic partners with virtual screening 10⁸-10⁹ compounds, BenevolentAI baricitinib for COVID-19 FDA EUA 2020 (Lilly partnership), Halicin antibiotic AI-discovered (Stokes 2020 Cell from 2, 335 training + 107M compound screen, novel mechanism proton motive force disruption), AI hit rate 25% vs random HTS 0. 5% (50× improvement), AI accelerates discovery from 14 to 9. 8 years (-30%), 70+ preclinical + 25+ clinical AI-discovered drugs in pipeline as of 2024. Phase 234 covers FDA regulation and clinical trials: Kefauver-Harris 1962 post-Thalidomide tragedy mandating efficacy proof, FDA standard review 10 months, Priority Review 6 months, Breakthrough Therapy designation 2012, Phase II → III 30% success rate (bottleneck), global regulators (FDA 45% market, EMA 22%, NMPA 11%, PMDA 8%, MHRA 4%), ICH 17 members + 33 observers harmonization, RECOVERY trial UK 2020 50, 000 patients adaptive master protocol demonstrating dexamethasone mortality 35% reduction in severe COVID, in silico clinical trials with virtual cohorts up to 100K (Alzheimer model), FDA Modeling and Simulation Working Group 2017+. Phase 235 integrates Kₚharma: 32-vertex polytope (367 edges, top deg = 31, mean degree 22. 94). #32 strong couplings: #26 Immune (0. 95 IO/Ab), #5 Cancer (0. 95 chemo+IO), #30 Genome (0. 92 CRISPR/PGx), #2 AI (0. 90 Insilico/AlphaFold), #6 Aging (0. 90 Lecanemab), #7 Psych (0. 85 psilocybin), #28 Neuro (0. 85 Aducanumab), #31 Photon (0. 85 AlphaFold). Average coupling 0. 847. ITU axiom δS = δ⟨K⟩ verified to machine precision (1. 000000) in 11+ pharmacological contexts spanning disease/treated states, agonist activation modes (full/biased), pharmacokinetic phenotypes (EM/PM), antibody mechanisms (ADC/bispecific), immune therapies (vaccine/checkpoint/CAR-T), AI design (virtual screening/generative), and regulatory decisions (approve/reject/accelerated). Ten falsifiable predictions for 2026-2032 (Pₐvg = 0. 730, Strong/Medium/Weak = 8/2/0): AI drug discovery 5+ FDA approvals 2030 (P=0. 80), CAR-T solid tumor first FDA approval 2028 (P=0. 70), ADC market 50B 2030 (P=0. 85), GLP-1 5+ additional adaptations (CV/Alzheimer/addiction) 2030 (P=0. 85), All hospitals PGx routine testing 2030 (P=0. 70), Cancer neoantigen mRNA standard 2028 (P=0. 80), FDA AI/ML drug regulatory framework complete 2027 (P=0. 80), Trispecific antibody FDA approval 2028 (P=0. 70), Digital twin clinical trial regulatory acceptance 2030 (P=0. 65), Universal cancer vaccine 2032 (P=0. 45). Central thesis: Kₚharma is the molecular intervention K-state of medicine, integrating chemistry, biology, immunology, genomics, and AI. The ITU axiom δS = δ⟨K⟩ specializes to Kₚharma as the pharmacology backbone. Pass-1 extension paper #2 completing Block B life sciences (6/6 papers: Kᵢmmune + Kₘicrobe + Kₙeuro + Kdev + Kgenome + Kₚharma). Eight Nobel Prizes featured: 1972 Edelman-Porter (antibody structure), 1984 Köhler-Milstein (hybridoma technology), 2003 MacKinnon (K+ channel structure), 2012 Lefkowitz-Kobilka (GPCR structural pharmacology), 2018 Allison-Honjo (checkpoint inhibitor immunotherapy), 2020 Doudna-Charpentier (CRISPR-Cas9 gene editing), 2023 Karikó-Weissman (pseudouridine mRNA), 2024 Baker-Hassabis-Jumper (AlphaFold + protein design).

Read Full Paperexternally

Bookmark

View Full Paper

Cite This Study

Munehiro Terada (Sun,) studied this question.

synapsesocial.com/papers/6a0bfda5166b51b53d378fa0 https://doi.org/https://doi.org/10.5281/zenodo.20258191

Bookmark

View Full Paper